Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Retained Earnings: 2017-2025

Historic Retained Earnings for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to -$1.4 billion.

  • Arcus Biosciences' Retained Earnings fell 32.85% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 32.85%. This contributed to the annual value of -$1.1 billion for FY2024, which is 33.33% down from last year.
  • As of Q3 2025, Arcus Biosciences' Retained Earnings stood at -$1.4 billion, which was down 10.85% from -$1.2 billion recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Retained Earnings ranged from a high of -$275.0 million in Q4 2021 and a low of -$1.4 billion during Q3 2025.
  • Its 3-year average for Retained Earnings is -$979.3 million, with a median of -$946.0 million in 2024.
  • Examining YoY changes over the last 5 years, Arcus Biosciences' Retained Earnings showed a top increase of 16.21% in 2021 and a maximum decrease of 100.75% in 2021.
  • Quarterly analysis of 5 years shows Arcus Biosciences' Retained Earnings stood at -$275.0 million in 2021, then slumped by 97.09% to -$542.0 million in 2022, then tumbled by 56.64% to -$849.0 million in 2023, then plummeted by 33.33% to -$1.1 billion in 2024, then slumped by 32.85% to -$1.4 billion in 2025.
  • Its Retained Earnings was -$1.4 billion in Q3 2025, compared to -$1.2 billion in Q2 2025 and -$1.2 billion in Q1 2025.